Epimmune Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology.
The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover T-cell epitopes that are potentially useful as prophylactic and therapeutic vaccines.
The patented technology enables rational design of disease-specific vaccines to treat and prevent certain cancers and infectious diseases, including hepatitis C, hepatitis B, AIDS and malaria.
“We believe our discoveries will enable a new generation of vaccines for diseases that have eluded traditional vaccine approaches,” said Deborah A. Schueren, Epimmune’s President and CEO.
“The patented technology gives meaning to the vast array of information being compiled in genomic and protein databases worldwide on all manner of disease-specific antigens.
Our technology will enable us to translate enormous amounts of raw genetic and biological data into specific vaccine candidates, further expanding our product pipeline.”
“The issuance of this pioneering patent creates a strong proprietary position for the Company’s epitope technology, and it sets a precedent in our efforts to broadly protect our core vaccine technology.
Epimmune has an extensive portfolio of applications to related technologies pending before the U.S. and numerous foreign patent offices,” said Timothy J. Lithgow, M.D., J.D., Director, Intellectual Property at Epimmune.
Epimmune develops novel vaccines for infectious diseases and cancer, building on its expertise and intellectual property in the field of T-cell recognition and activation.
In the cancer field, Epimmune is collaborating with G.D. Searle & Co., a wholly-owned subsidiary of Monsanto Co., to develop immune stimulating products for the treatment of breast, colon, lung and prostate cancers.
Epimmune is also pursuing development of therapeutic vaccines for hepatitis C, hepatitis B and HIV, and prophylactic vaccines for hepatitis C, HIV and malaria.